Regulatory Information
APEX PHARMA MARKETING PTE. LTD.
APEX PHARMA MARKETING PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
TABLET, FILM COATED
**Dosage and Administration** To be administered orally. _Hypertension:_ 2.5 mg daily, to be taken in the morning. The action of Indapamide is progressive and the reduction in blood pressure may continue and not reach a maximum until several months after the initiation of therapy. A larger dose than 2.5 mg Indapamide is not recommended as there is no appreciable antihypertensive effect but a diuretic effect may become apparent.
ORAL
Medical Information
**Indications** Rinalix is indicated for the treatment of essential hypertension, alone or in combination with other antihypertensive drugs.
**Contraindications** Anuria, stroke, recent cerebrovascular accident, severe hepatic insufficiency, known hypersensitivity to indapamide or to other sulfonamide-derived drugs.
C03BA11
indapamide
Manufacturer Information
APEX PHARMA MARKETING PTE. LTD.
XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD
Active Ingredients
Documents
Package Inserts
Rinalix Tab PI.pdf
Approved: February 21, 2022